Last reviewed · How we verify
Leukotriene Receptor Antagonist
Leukotriene Receptor Antagonist is a Leukotriene receptor antagonist Small molecule drug developed by King Abdullah International Medical Research Center. It is currently in Phase 3 development for Asthma (persistent mild to moderate), Allergic rhinitis, Exercise-induced bronchoconstriction.
Leukotriene receptor antagonists block cysteinyl leukotriene receptors on airway and immune cells, reducing inflammatory mediator signaling.
Leukotriene receptor antagonists block cysteinyl leukotriene receptors on airway and immune cells, reducing inflammatory mediator signaling. Used for Asthma (persistent mild to moderate), Allergic rhinitis, Exercise-induced bronchoconstriction.
At a glance
| Generic name | Leukotriene Receptor Antagonist |
|---|---|
| Sponsor | King Abdullah International Medical Research Center |
| Drug class | Leukotriene receptor antagonist |
| Target | Cysteinyl leukotriene receptors (CysLT1, CysLT2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Immunology |
| Phase | Phase 3 |
Mechanism of action
Leukotrienes are potent inflammatory mediators released by mast cells and eosinophils that promote airway constriction, mucus secretion, and eosinophil recruitment. By antagonizing cysteinyl leukotriene receptors (CysLT1 and CysLT2), these drugs suppress the inflammatory cascade underlying asthma and allergic airway disease. This reduces bronchoconstriction, airway hyperresponsiveness, and eosinophilic inflammation.
Approved indications
- Asthma (persistent mild to moderate)
- Allergic rhinitis
- Exercise-induced bronchoconstriction
Common side effects
- Headache
- Elevated liver enzymes
- Neuropsychiatric events (rare)
- Gastrointestinal disturbance
Key clinical trials
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) (PHASE2)
- Observational Study on the Impact of Obstructive Sleep Apnea on Executive Function and Empathy Development in Children
- A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA
- A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
- Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia (NA)
- Asthma Research in Children and Adolescents
- Transporter Mediated Uptake of Montelukast (NA)
- Genotype Stratified Pharmacokinetic Study of Montelukast (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leukotriene Receptor Antagonist CI brief — competitive landscape report
- Leukotriene Receptor Antagonist updates RSS · CI watch RSS
- King Abdullah International Medical Research Center portfolio CI
Frequently asked questions about Leukotriene Receptor Antagonist
What is Leukotriene Receptor Antagonist?
How does Leukotriene Receptor Antagonist work?
What is Leukotriene Receptor Antagonist used for?
Who makes Leukotriene Receptor Antagonist?
What drug class is Leukotriene Receptor Antagonist in?
What development phase is Leukotriene Receptor Antagonist in?
What are the side effects of Leukotriene Receptor Antagonist?
What does Leukotriene Receptor Antagonist target?
Related
- Drug class: All Leukotriene receptor antagonist drugs
- Target: All drugs targeting Cysteinyl leukotriene receptors (CysLT1, CysLT2)
- Manufacturer: King Abdullah International Medical Research Center — full pipeline
- Therapeutic area: All drugs in Respiratory / Immunology
- Indication: Drugs for Asthma (persistent mild to moderate)
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Exercise-induced bronchoconstriction
- Compare: Leukotriene Receptor Antagonist vs similar drugs
- Pricing: Leukotriene Receptor Antagonist cost, discount & access